Equities Analysts Offer Predictions for Hookipa Pharma Inc’s FY2027 Earnings (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 earnings estimates for Hookipa Pharma in a research note issued to investors on Thursday, March 16th. HC Wainwright analyst A. He expects that the company will post earnings of $0.35 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.93) per share.

Separately, Bank of America downgraded shares of Hookipa Pharma from a “buy” rating to an “underperform” rating in a research note on Friday, December 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Hookipa Pharma Trading Down 1.2 %

HOOK stock opened at $0.82 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.98 and a current ratio of 4.98. The company’s 50-day simple moving average is $0.93 and its 200 day simple moving average is $1.07. Hookipa Pharma has a 52 week low of $0.72 and a 52 week high of $2.39. The company has a market capitalization of $44.86 million, a PE ratio of -0.54 and a beta of 0.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new position in shares of Hookipa Pharma in the fourth quarter valued at approximately $849,000. Millennium Management LLC acquired a new position in shares of Hookipa Pharma in the second quarter valued at approximately $1,145,000. Alyeska Investment Group L.P. acquired a new position in shares of Hookipa Pharma in the first quarter valued at approximately $1,434,000. Vanguard Group Inc. increased its stake in shares of Hookipa Pharma by 22.6% in the first quarter. Vanguard Group Inc. now owns 1,118,871 shares of the company’s stock valued at $2,551,000 after buying an additional 206,309 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of Hookipa Pharma by 311.4% in the fourth quarter. Two Sigma Investments LP now owns 155,806 shares of the company’s stock valued at $126,000 after buying an additional 117,932 shares during the period. Institutional investors own 52.30% of the company’s stock.

About Hookipa Pharma

(Get Rating)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.